What D Lira Treats: Main Uses and Benefits

D Lira is commonly used across conditions presenting with symptomatic discomfort related to vascular function. The primary therapeutic goal is to provide supportive relief and maintain functional stability in two distinct domains: erectile dysfunction (ED) and the chronic management of Pulmonary Arterial Hypertension (PAH).

The medication is relevant for adult men to manage the cluster of symptoms associated with ED, which involves the inability to achieve or maintain a satisfactory penile erection. When symptoms create noticeable physiological strain, D Lira may assist with managing symptoms related to the inability to achieve an erection. This helps patients cope more steadily with symptom fluctuations, providing support that assists with maintaining functional stability and contributing to improved sexual comfort.

For patients with PAH, D Lira is applied in clinical settings to address symptoms related to systemic imbalance, such as shortness of breath and fatigue, which interfere with daily functioning. By easing this symptomatic burden, the medication helps to improve day-to-day comfort.

“This supportive therapeutic benefit contributes to improved comfort during periods of heightened symptoms.”

---

Quick Fact: Relief for Vascular Impairment The medication is considered relevant for use across domains where additional symptomatic support is needed, helping to maintain a sense of stability when symptoms are more noticeable.

---

Regulatory References

1. NIH MedlinePlus Drug Information

D Lira (Sildenafil) is governed by strict population eligibility rules established by regulatory authorities.

Absolute Prohibitions (Contraindications)

Use of this medicine is absolutely contraindicated in patients taking any form of organic nitrate or nitric oxide donor, including street drugs, due to the high risk of dangerously severe drops in blood pressure. Contraindication also applies to individuals with a known hypersensitivity to Sildenafil, recent history of stroke or myocardial infarction (heart attack), and those with severe hepatic (liver) impairment.

Individuals with hypotension (low blood pressure below 90/50 mmHg) or certain pre-existing eye conditions, such as Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) or hereditary degenerative retinal disorders, must also not use the drug.

Age and Condition-Based Restrictions

• The medicine is not indicated for women for the treatment of Erectile Dysfunction, nor is it intended for individuals under 18 years of age for this use.
• Specific caution and monitoring are required for patients with severe renal (kidney) impairment or those who are older adults (ge 65 years); these populations may require consideration for a lower initial dose.
• Restrictions apply to individuals with anatomical deformation of the penis or conditions that predispose them to priapism (e.g., sickle cell anemia, multiple myeloma).

These regulations define precise boundaries for D Lira use, ensuring the medication is only administered to populations that meet specific label criteria.

Interactions with other medicines and products

Interaction Scope

The interaction profile of D Lira (Sildenafil) is structured by specific pharmacological effects and metabolic pathways as documented in official regulatory sources (FDA, EMA).

Property	Official Regulatory Statement
Medicinal Product Categories	Organic Nitrates, Guanylate Cyclase Stimulators, Alpha-Blockers, CYP3A4 Inhibitors, CYP3A4 Inducers.
Mechanistic Basis	Pharmacodynamic Potentiation: Potentiation of hypotensive effects. Pharmacokinetic: Reduced clearance via inhibition of CYP3A4 (major route); Increased clearance via induction of CYP3A4.
Timing-Based Rules	Potential for symptomatic hypotension with Alpha-Blockers is most likely to occur within 4 hours post-dosing. Co-administration with Ritonavir requires a maximum dose constraint within a 48-hour period.
Food/Substance Notes	Grapefruit juice may cause a modest increase in plasma Sildenafil exposure. A high-fat meal delays the rate of absorption ( Tmax delay and Cmax reduction).
Population-Specific Notes	Severe Renal Impairment ( Creatinine clearance < 30 mL/ min) and Hepatic Impairment (e.g., cirrhosis) both result in reduced Sildenafil clearance, leading to higher systemic exposure.

Interaction Classifications

Property	Restriction/Classification (As Defined in Official Documents)
Absolute Contraindication	Co-administration with Organic Nitrates (all forms) and Riociguat is contraindicated due to the severe risk of symptomatic hypotension.
High-Risk Exposure Agents	Potent CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) significantly increase Sildenafil plasma exposure. Co-administration with other PDE5 Inhibitors is not recommended.
Additive Effects	Use with Alpha-Blockers may lead to an additive blood pressure-lowering effect. Patients must be stable on alpha-blocker therapy before initiating Sildenafil treatment.

Connection to the Overall Interaction Profile

Regulatory documents define the interaction structure primarily through the pharmacodynamic risk of potentiated vasodilation, which mandates absolute contraindications, and the pharmacokinetic risk of altered clearance via the CYP3A4 pathway. This framework establishes constraints for co-administered agents and identifies specific patient populations where reduced clearance naturally increases systemic exposure.

How D Lira Works (Sildenafil)

D Lira, whose active ingredient is Sildenafil, modulates vascular smooth muscle tone through its role as a selective competitive inhibitor of the Phosphodiesterase type 5 (PDE5) enzyme. This action is peripheral, targeting PDE5 primarily within specific vascular beds.

The fundamental interaction occurs when Sildenafil temporarily blocks PDE5, an enzyme responsible for hydrolyzing the signaling molecule cyclic Guanosine Monophosphate (cGMP). By inhibiting this breakdown, the drug causes cGMP to accumulate within the smooth muscle cells.

This sustained cGMP concentration augments the Nitric Oxide (NO)-cGMP signaling pathway, initiating a molecular cascade that lowers the concentration of intracellular calcium ions (Ca^2+). This reduction in calcium is the direct cellular mechanism that results in the relaxation of vascular smooth muscle. The resulting physiological consequence is vasodilation, which increases local blood flow (perfusion) to target tissues. This mechanism is conditional, as it requires the prior release of NO to complete the signaling cascade.

How to Use D Lira

The usage of D Lira (Sildenafil) is determined by separate administration protocols, which govern the required dosage, frequency, and administration route based on the intended use. The medicine is primarily available for oral administration as a film-coated tablet, although an oral suspension and an intravenous injection are also recognized forms.

---

Administration Guidelines

Usage Regimen	Dosing Schedule	Frequency Pattern
As-Needed Use	Starting dose is typically 50 mg, with a maximum dose of 100 mg.	Maximum of once per day (as needed).
Fixed-Schedule Use (PAH)	Standard oral dose is 20 mg, administered three times a day (TID).	Doses must be taken approximately 4 to 6 hours apart.

---

Contextual and Population-Specific Rules

Timing and Food: The as-needed tablet is to be taken orally between 30 minutes and 4 hours prior to activity. It may be administered with or without food; however, ingestion with a high-fat meal can delay the medicine's time to onset.

Special Conditions: For patients on the as-needed regimen who are 65 years of age or older or who have severe renal or hepatic impairment, a reduced starting dose of 25 mg is typically considered. The intravenous formulation (10 mg IV bolus) is reserved for patients on the PAH regimen who are temporarily unable to tolerate the oral form.

Research Evidence / Overview of Studies for D Lira

The clinical understanding of D Lira (Sildenafil) is based on formal research, primarily through controlled clinical trials, systematic reviews, and meta-analyses. The focus of this research has been on specific conditions associated with functional and systemic imbalance, as documented in authoritative regulatory sources.

---

Evidence for Use in Erectile Dysfunction (ED)

Research into D Lira for treating the symptoms of Erectile Dysfunction (ED) relies heavily on short-term, randomized, placebo-controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing the observed patterns in men receiving D Lira to those receiving an inactive control (placebo). The research examined outcomes related to physical discomfort using standardized tools, such as the International Index of Erectile Function (IIEF) score, and by monitoring the number of successful sexual intercourse attempts.

Studies report how symptoms evolved in the observed populations, noting patterns related to changes measured in the ability to achieve and maintain an erection compared to participants who received the placebo. A key limitation is that the majority of trials were designed to compare D Lira against a placebo, and the response was studied for men who were already undergoing sexual stimulation in the research context.

---

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Research was conducted using short-term, controlled trials, applied in studies examining patient-reported experiences and physiological function in patients diagnosed with chronic Pulmonary Arterial Hypertension (PAH). The main functional measure used is the 6-Minute Walk Distance (6MWD). Studies also monitored outcomes related to systemic or functional imbalance by measuring changes in the pressures and resistance within the pulmonary arteries. Studies report how symptoms evolved in the observed populations, describing patterns related to changes measured in exercise capacity and shifts in pulmonary hemodynamic measurements.

Comparative evidence is lacking, as there are limited trials that directly compare D Lira's long-term outcomes against all other major classes of PAH-specific therapies.

---

Long-Term Evidence and Follow-up

While the initial regulatory decisions for both ED and PAH were based on short-term randomized controlled trials, later, open-label extension studies were conducted. These studies monitored responses over defined time intervals that sometimes spanned several years. Long-term effects are not fully established under the controlled conditions of an RCT. Data are still emerging regarding the durability of responses over many years of continuous use.

Key Studies & References

1. Effects of Different Doses of Sildenafil for Pulmonary Arterial Hypertension (Trial Review)
2. Label: SILDENAFIL tablet, film coated (FDA Labeling for Erectile Dysfunction)
3. Label: SILDENAFIL tablet (FDA Labeling for Pulmonary Arterial Hypertension)

Common questions about D Lira (FAQ)

Q: What happens if I stop taking D Lira suddenly?

Regulatory documents do not report specific withdrawal symptoms upon sudden discontinuation of D Lira. However, if the medicine is being used for Pulmonary Arterial Hypertension (PAH), it is generally recommended that any changes to the regimen, including stopping use, be discussed with the prescribing physician.

Q: Does D Lira interact with common over-the-counter pain relievers?

Official guidance recommends that you discuss all medicines, including over-the-counter (OTC) pain relievers, with your healthcare provider. This is because the safety of combining D Lira with every non-prescription drug may not have been fully evaluated in the official product information.

Q: Why is D Lira usually given as an injection, not a pill?

D Lira is available in several forms, including oral tablets and an intravenous injection. The injection form is typically reserved for individuals on the fixed-schedule treatment who are temporarily unable to take the medicine by mouth. The primary form used depends on the specific therapeutic need.

Q: Can I use D Lira if I have a history of depression or anxiety?

Official product information does not list a history of depression or anxiety as a reason to avoid using D Lira. However, side effects that affect the nervous system, such as dizziness and headache, are reported in clinical data.

Q: What happens if I forget a dose of D Lira?

If you forget a dose while on the fixed-schedule regimen, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, regulatory guidance indicates that you should skip the missed dose. It is generally advised not to take a double dose to make up for a missed one.

Q: Are there specific vitamins or supplements that interact with D Lira?

Official regulatory documents advise caution regarding the use of D Lira with herbal remedies, vitamins, or supplements. The safety of combining the medicine with every possible supplement may not have been fully established in official trials.

Q: Is D Lira known to cause hair loss?

Studies and official regulatory documents do not list hair loss as a common or serious adverse reaction associated with D Lira.

Q: Do official documents mention any effects of D Lira on mood?

Official documents list effects on the nervous system, such as headache and dizziness. However, regulatory adverse reaction tables do not specifically list mood swings or depression as common side effects of D Lira.

Q: What is the common age range of people using D Lira?

The approved age range for D Lira varies based on the condition being addressed. For Erectile Dysfunction (ED), it is indicated for adult men aged 18 and older. For Pulmonary Arterial Hypertension (PAH), official labeling includes both adults and children aged 1 year and older.

Q: What should I do if the injection site is red or sore?

Official product information notes that injection site reactions are a common side effect of the injectable form of D Lira. These reactions are typically mild and may include redness, itching, or soreness at the area where the injection was given.

Q: Is the medication D Lira considered a 'new' drug?

The active ingredient in D Lira, Sildenafil, is not considered a new compound. Official records show that it was first approved by the U.S. FDA for its initial use in March 1998.

Q: What are the common misunderstandings people have about D Lira?

Official patient information clarifies certain misunderstandings about D Lira. For its ED use, the medicine requires sexual stimulation to work effectively. It is also important to note that the medicine does not protect against sexually transmitted diseases (STDs).

Q: Does D Lira interfere with consuming alcohol?

Moderate consumption of alcohol is generally permitted while using D Lira. However, official guidance suggests avoiding excessive alcohol consumption, as this may make it more difficult for the medicine to achieve its intended therapeutic effect.

Q: What is the connection between D Lira and the pancreas?

Regulatory documents describe a connection between D Lira use and a reported risk of acute pancreatitis. This condition, which is the inflammation of the pancreas, is listed as an uncommon but clinically significant adverse reaction in the official product information.

Q: What information is available regarding D Lira use during pregnancy?

According to official regulatory documents, the use of D Lira during pregnancy is generally not recommended. This caution is based on the fact that data regarding human pregnancy exposure and the associated risks are limited.

Q: Is D Lira the same type of drug as [Name of similar class drug]?

The active ingredient in D Lira, Sildenafil, is officially classified as a selective Phosphodiesterase type 5 (PDE5) inhibitor. This classification defines its precise mechanism of action and distinguishes it from other drug classes.

Q: Is it normal to feel less hungry when taking D Lira?

Official documentation states that gastrointestinal side effects are very common, especially when starting treatment. While feeling less hungry is not specifically listed, common side effects in this area include nausea and diarrhea.

Q: Are the side effects of D Lira generally mild?

Official documentation indicates that many reported side effects, such as headache and nausea, are often mild to moderate and may resolve over time. However, the regulatory warnings section also documents certain serious adverse reactions, which require careful consideration by a healthcare professional.

Q: Do I need to change my diet while using D Lira?

Specific dietary restrictions are not generally required while using D Lira. Official guidance notes that ingesting the medicine with a high-fat meal may delay how quickly it starts to work. Additionally, it is advised that grapefruit juice should be avoided when using the medicine for Pulmonary Arterial Hypertension (PAH).

Q: Is D Lira typically used long-term or short-term?

The typical duration of use is defined by the condition being treated. When used for Pulmonary Arterial Hypertension (PAH), official studies have examined continuous, long-term use. When used for Erectile Dysfunction (ED), the medicine is typically taken only as-needed before activity.

Q: Is D Lira safe for someone who has had pancreatitis in the past?

Official warnings describe a risk of acute pancreatitis during treatment and advise against restarting the medicine if the condition is confirmed. The regulatory documents do not explicitly address the use of D Lira in patients who have a pre-existing history of pancreatitis.

Q: Does taking D Lira cause low blood sugar (hypoglycemia)?

The risk of developing hypoglycemia, or low blood sugar, is listed as a common side effect only when D Lira is used in combination with certain other diabetes medications, such as insulin or a sulfonylurea.

Q: Is D Lira approved for use in children?

Approved use in children is restricted by the indication. For the treatment of Pulmonary Arterial Hypertension (PAH), the medicine is indicated for children aged 1 year and older. However, official documents state that D Lira is not indicated for Erectile Dysfunction in individuals under 18 years of age.

Q: What is the purpose of the initial lower dose of D Lira?

Official documents advise considering a reduced initial dose for specific patient populations, such as older adults or those with severe impairment of the kidneys or liver. This reduced dose is intended to compensate for the possibility of reduced drug clearance in these individuals, which could otherwise lead to higher levels of the medicine in the body.

Q: What is the typical time frame for the dose to be increased?

The official label details two distinct dosing protocols (as-needed and fixed-schedule). Regulatory documents state that any decision to adjust or increase the dose is based on the individual patient's tolerability and efficacy response as determined by a healthcare professional.

Q: Can D Lira be used by people with heart problems?

Official regulatory documents establish restrictions for use in individuals with certain heart and circulatory conditions. The medicine is contraindicated for people with a recent history of a stroke or myocardial infarction (heart attack), as well as those with significantly low blood pressure (hypotension).

Q: Can D Lira be taken at any time of day?

The appropriate time of day for taking D Lira depends on the regimen being followed. The as-needed use provides flexibility, but the fixed-schedule use for Pulmonary Arterial Hypertension (PAH) requires that doses be taken at the same time each day, spaced approximately 4 to 6 hours apart.

Q: Why is D Lira sometimes called a GLP-1 receptor agonist?

According to official product documents, the active ingredient Sildenafil is officially classified as a selective Phosphodiesterase type 5 (PDE5) inhibitor.

Q: Can people who are allergic to certain foods use D Lira?

Official product information contraindicates use for patients with a known hypersensitivity to the active ingredient, Sildenafil, or any of the non-active ingredients used in the formulation. Specific warnings regarding common food allergens are not typically listed in the core safety information.

Q: Do studies show D Lira helps with [Specific, common co-occurring condition]?

The documented clinical trials and research primarily support the use of D Lira for two indications: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). Evidence from controlled trials focusing on other co-occurring conditions is limited.

D Lira (Sildenafil tablet) must be stored and handled according to specific, officially documented requirements to maintain its stability and effectiveness.

Storage Requirements

The tablets require storage at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). To prevent degradation, the product must be protected from both moisture and excessive light. Storage in high-humidity areas, such as a bathroom, is prohibited. The medicine must be kept in the original container, and the container must be kept tightly closed.

Child Safety and Disposal

All D Lira tablets must be kept out of the sight and reach of children at all times. Disposal of any unused or expired medication should be conducted through a recognized drug take-back program. Regulatory guidelines prohibit throwing the medicine into wastewater or flushing it down a toilet.